Medtronic plc [NYSE: MDT] slipped around -0.69 points on Wednesday, while shares priced at $113.94 at the close of the session, down -0.60%. The company report on December 21, 2020 that Medtronic receives Health Canada licence for Micra™ AV, the world’s smallest pacemaker which can now treat AV block.
More Patients in Canada Are Now Candidates for a Leadless Pacing Option.
BRAMPTON, ON, Dec. 21, 2020 /CNW/ – Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) announced that it has received a Health Canada licence for Micra™ AV, the world’s smallest pacemaker with atrioventricular (AV) synchrony. Micra AV is indicated for the treatment of patients with AV block, a condition in which the electrical connection between the chambers of the heart (the atria and the ventricle) is impaired. Medtronic’s groundbreaking technology is the first and currently the only Health Canada-licensed leadless pacemaker portfolio, now expanding the range of eligible Canadian patients that can be implanted.
Medtronic plc stock is now 0.43% up from its year-to-date (YTD) trading value. MDT Stock saw the intraday high of $115.59 and lowest of $113.92 per share. The company’s 52-week high price is 122.15, which means current price is +57.96% above from all time high which was touched on 01/22/20.
Compared to the average trading volume of 4.65M shares, MDT reached a trading volume of 2373444 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Medtronic plc [MDT]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MDT shares is $127.13 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MDT stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Medtronic plc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 15, 2020. While these analysts kept the previous recommendation, Goldman raised their target price from $100 to $119. The new note on the price target was released on December 15, 2020, representing the official price target for Medtronic plc stock. Previously, the target price had yet another raise to $125, while Stifel analysts kept a Buy rating on MDT stock.
The Average True Range (ATR) for Medtronic plc is set at 2.28, with the Price to Sales ratio for MDT stock in the period of the last 12 months amounting to 5.44. The Price to Book ratio for the last quarter was 3.05, with the Price to Cash per share for the same quarter was set at 10.73. Price to Free Cash Flow for MDT in the course of the last twelve months was 86.76 with Quick ratio for the last quarter at 1.80.
How has MDT stock performed recently?
Medtronic plc [MDT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.90. With this latest performance, MDT shares gained by 2.68% in over the last four-week period, additionally plugging by 28.22% over the last 6 months – not to mention a rise of 0.15% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MDT stock in for the last two-week period is set at 53.85, with the RSI for the last a single of trading hit 51.67, and the three-weeks RSI is set at 54.62 for Medtronic plc [MDT]. The present Moving Average for the last 50 days of trading for this stock 110.37, while it was recorded at 115.01 for the last single week of trading, and 100.51 for the last 200 days.
Medtronic plc [MDT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Medtronic plc [MDT] shares currently have an operating margin of +19.42 and a Gross Margin at +61.87. Medtronic plc’s Net Margin is presently recorded at +16.56.
Return on Total Capital for MDT is now 7.38, given the latest momentum, and Return on Invested Capital for the company is 6.47. Return on Equity for this stock inclined to 9.50, with Return on Assets sitting at 5.31. When it comes to the capital structure of this company, Medtronic plc [MDT] has a Total Debt to Total Equity ratio set at 50.74. Additionally, MDT Total Debt to Total Capital is recorded at 33.66, with Total Debt to Total Assets ending up at 28.38. Long-Term Debt to Equity for the company is recorded at 44.93, with the Long-Term Debt to Total Capital now at 29.81.
Reflecting on the efficiency of the workforce at the company, Medtronic plc [MDT] managed to generate an average of $53,211 per employee. Receivables Turnover for the company is 5.32 with a Total Asset Turnover recorded at a value of 0.32.Medtronic plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 2.20.
Earnings analysis for Medtronic plc [MDT]
With the latest financial reports released by the company, Medtronic plc posted 1.44/share EPS, while the average EPS was predicted by analysts to be reported at 1.38/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MDT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Medtronic plc go to 10.19%.
Insider trade positions for Medtronic plc [MDT]
There are presently around $124,022 million, or 83.50% of MDT stock, in the hands of institutional investors. The top three institutional holders of MDT stocks are: BLACKROCK INC. with ownership of 112,167,184, which is approximately 0.861% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 111,875,583 shares of the stock with an approximate value of $12.75 billion in MDT stocks shares; and STATE STREET CORP, currently with $6.61 billion in MDT stock with ownership of nearly -1.487% of the company’s market capitalization.
Positions in Medtronic plc stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 936 institutional holders increased their position in Medtronic plc [NYSE:MDT] by around 40,725,276 shares. Additionally, 769 investors decreased positions by around 53,180,925 shares, while 205 investors held positions by with 994,580,916 shares. The mentioned changes placed institutional holdings at 1,088,487,117 shares, according to the latest SEC report filing. MDT stock had 150 new institutional investments in for a total of 6,998,485 shares, while 90 institutional investors sold positions of 5,706,343 shares during the same period.